Adial Pharmaceuticals
ADIL
13 hedge funds and large institutions have $1.24M invested in Adial Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
7% less funds holding
Funds holding: 14 → 13 (-1)
19% less capital invested
Capital invested by funds: $1.53M → $1.24M (-$290K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$145K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$35.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$18.9K |
| 4 |
Renaissance Technologies
New York
|
+$10.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AGM
Alpine Global Management
New York
|
-$85K |
| 2 |
VF
Virtu Financial
New York
|
-$42K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$27K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$2.36K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
BlackRock
New York
| $350K | – | – | – |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $335K | – | – | – |
|
|
3
Renaissance Technologies
New York
| $168K | +$10.6K | +9 | +6% |
|
4
Geode Capital Management
Boston,
Massachusetts
| $132K | – | – | – |
|
|
5
Citadel Advisors
Miami,
Florida
| $131K | +$145K | +123 | New |
|
6
Brown Advisory
Baltimore,
Maryland
| $44K | – | – | – |
|
|
7
Dimensional Fund Advisors
Austin,
Texas
| $32K | +$35.4K | +30 | New |
|
|
8
UBS Group
Zurich,
Switzerland
| $19K | +$18.9K | +16 | +800% |
|
9
Commonwealth Equity Services
Waltham,
Massachusetts
| $18K | – | – | – |
|
|
10
Osaic Holdings
Scottsdale,
Arizona
| $9K | -$2.36K | -2 | -20% |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $3K | -$1.18K | -1 | -25% |
|
12
Morgan Stanley
New York
| $1K | – | – | – |
|
13
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
AGM
14
Alpine Global Management
New York
| – | -$85K | -61 | Closed |
|
|
VF
15
Virtu Financial
New York
| – | -$42K | -30 | Closed |
|
|
16
Northern Trust
Chicago,
Illinois
| – | -$27K | -19 | Closed |
|
ADIL Hedge Fund Activity: Q4 2020 in Review
13 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q4 2020, worth a combined $1.24M — down 19% from $1.53M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ADIL and 2 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $145K. The largest seller was Alpine Global Management, exiting entirely with an estimated $85K sold.
- 13 institutional investors held Adial Pharmaceuticals (ADIL) as of Q4 2020, down from 14 in Q3 2020.
- Funds reported $1.24M of Adial Pharmaceuticals stock for Q4 2020, down 19% quarter-over-quarter.
- 2 funds opened new Adial Pharmaceuticals positions in Q4 2020 and 3 closed out, a net change of -1 holder.
- The largest Adial Pharmaceuticals buyer in Q4 2020 was Citadel Advisors, an estimated $145K added.
- The largest Adial Pharmaceuticals seller in Q4 2020 was Alpine Global Management, an estimated $85K sold.
Based on aggregated 13F filings for Q4 2020.